These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 16014683)

  • 1. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.
    Yazdani-Biuki B; Stadlmaier E; Mulabecirovic A; Brezinschek R; Tilz G; Demel U; Mueller T; Brickmann K; Graninger WB; Brezinschek HP
    Ann Rheum Dis; 2005 Aug; 64(8):1224-6. PubMed ID: 16014683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
    Cambridge G; Leandro MJ; Edwards JC; Ehrenstein MR; Salden M; Bodman-Smith M; Webster AD
    Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
    Mathsson L; Lampa J; Mullazehi M; Rönnelid J
    Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
    Guis S; Balandraud N; Bouvenot J; Auger I; Toussirot E; Wendling D; Mattei JP; Nogueira L; Mugnier B; Legeron P; Landt O; Serre G; Roudier J; Roudier C
    Arthritis Rheum; 2007 Dec; 57(8):1426-30. PubMed ID: 18050183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
    Paulus HE; Wiesner J; Bulpitt KJ; Patnaik M; Law J; Park GS; Wong WK
    J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
    Toubi E; Kessel A; Slobodin G; Boulman N; Pavlotzky E; Zisman D; Rozenbaum M; Rosner I
    Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
    Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
    Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of IgG rheumatoid factor in patients with rheumatoid arthritis].
    Naka T; Kondo M; Mashima T
    Ryumachi; 1995 Jun; 35(3):530-7. PubMed ID: 7570206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
    Vis M; Bos WH; Wolbink G; Voskuyl AE; Twisk JW; Van de Stadt R; Hamann D; Dijkmans BA; Lems WF
    J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis.
    Sakthiswary R; Shaharir SS; Mohd Said MS; Asrul AW; Shahril NS
    Int J Rheum Dis; 2014 Nov; 17(8):872-7. PubMed ID: 25292482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis.
    Newkirk MM; Goldbach-Mansky R; Senior BW; Klippel J; Schumacher HR; El-Gabalawy HS
    Rheumatology (Oxford); 2005 Nov; 44(11):1433-41. PubMed ID: 16091399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.